Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER<sup>+</sup> invasive breast cancer (STAKT) by Robertson, John F. R. et al.
                                                                    
University of Dundee
Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363)
treatment of patients with ER+ invasive breast cancer (STAKT)
Robertson, John F. R.; Coleman, Robert E.; Cheung, Kwok-Leung; Evans, Abigail;
Holcombe, Chris; Skene, Anthony
Published in:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-19-3053
Publication date:
2020
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Robertson, J. F. R., Coleman, R. E., Cheung, K-L., Evans, A., Holcombe, C., Skene, A., Rea, D., Ahmed, S.,
Jahan, A., Horgan, K., Rauchhaus, P., Littleford, R., Cheung, S. A., Cullberg, M., de Bruin, E. C., Koulai, L.,
Lindemann, J. P. O., Pass, M., Rugman, P., ... Gee, J. M. W. (2020). Proliferation and AKT activity biomarker
analyses after Capivasertib (AZD5363) treatment of patients with ER
+
 invasive breast cancer (STAKT). Clinical
Cancer Research, 26(7), 1574-1585. https://doi.org/10.1158/1078-0432.CCR-19-3053
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jan. 2021
1 
 
 
Proliferation and AKT activity biomarker analyses after 
Capivasertib (AZD5363) treatment of patients with ER+ invasive 
breast cancer (STAKT) 
John FR Robertson,
1
 Robert E Coleman,
2
 Kwok-Leung Cheung,
3
 Abigail Evans,
4
 Chris 
Holcombe,
5
 Anthony Skene,
6
 Daniel Rea,
7
 Samreen Ahmed,
8
 Ali Jahan,
9
 Kieran 
Horgan,
10
 Petra Rauchhaus,
11
 Roberta Littleford,
11
 SY Amy Cheung,
12
* Marie Cullberg,
12
 
Elza C de Bruin,
12
 Loumpiana Koulai,
12
 Justin PO Lindemann,
12
 Martin Pass,
12
 Paul 
Rugman,
12
 Gaia Schiavon,
12
 Rahul Deb,
13
 Pauline Finlay,
14
 Andrew Foxley,
12
 and Julia 
MW Gee
14
  
 
1
University of Nottingham, Nottingham, UK; 
2
University of Sheffield, Sheffield, UK; 
3
University of Nottingham, Royal Derby Hospital Centre, Derby, UK; 
4
Poole Hospital 
NHS Foundation Trust, Poole, UK; 
5
Royal Liverpool University Hospital, Liverpool, UK; 
6
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, 
UK; 
7
University of Birmingham, Birmingham, UK; 
8
Leicester Royal Infirmary, Leicester, 
UK; 
9
King’s Mill Hospital, Nottingham, UK; 
10
Leeds General Infirmary, Leeds, UK; 
11
University of Dundee, Dundee, UK; 
12
IMED Biotech Unit, AstraZeneca, Cambridge, 
UK; 
13
Department of Histopathology, University Hospitals of Derby and Burton NHS 
Foundation Trust, Derby, UK; 
14
Cardiff University, Cardiff, UK 
 
*Affiliation at the time of this research. Current affiliation: Certara Strategic Consulting 
(CSC) Division, Certara, Princeton, NJ, USA 
 
Running title: Capivasertib rapidly targets key AKT pathway biomarkers 
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
2 
 
 
Corresponding author:  
John Robertson, Professor of Surgery 
Director, Centre of Excellence for Autoimmunity in Cancer  
University of Nottingham  
Graduate Entry Medical School 
Royal Derby Hospital 
Uttoxeter Road 
Derby, DE22 3DT, UK  
Tel: +44 (0)1332 340131 
Email: john.robertson@nottingham.ac.uk 
 
Keywords: Capivasertib; AKT inhibitor; breast cancer; AZD5363; STAKT 
 
Data from this manuscript were partially reported at the San Antonio Breast Cancer 
Symposium in San Antonio, TX, USA on December 5–9, 2017 and December 4–8, 
2018. 
 
Conflicts of interest: 
JFRR has received consulting fees from, and performed contracted research on behalf 
of, AstraZeneca, Bayer, Novartis, and Oncimmune, has given expert testimony for 
AstraZeneca, and holds stock with Oncimmune; REC has received consulting and/or 
speaker fees from Amgen, Astellas, Eisai, Genomic Health, Inbiomotion, and Scancell 
and is a patent holder for a biomarker developed by Inbiomotion; K-LC has received 
research funding from AstraZeneca and served as an advisory board member for 
Genomic Health; CH has received consultancy fees from Pfizer; RL and PF have 
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
3 
 
received funding from the University of Nottingham; JMWG has received research 
funding from AstraZeneca; SYAC, MC, ECB, LK,JPOL, MP, PR, GS, and AF are 
employees of and own stock with AstraZeneca;  AE, AS, DR, SA, AJ, KH, PR, RD, and 
PF have no conflicts to declare. 
  
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
4 
 
Statement of translational relevance 
Capivasertib (AZD5363) monotherapy previously demonstrated anticancer activity in 
Phase I trials in patients with advanced solid tumors, particularly those whose tumors 
harbored an AKT mutation. In the short time frame that window-of-opportunity studies 
permit, the STAKT study reported here determined that in primary breast cancers, 
capivasertib at the recommended monotherapy dose (480 mg twice daily [bid]) rapidly 
modulated the AKT pathway (after 4.5 days of treatment), as evidenced by significant 
decreases from baseline versus placebo in biomarkers of the AKT pathway (including 
pGSK3β and pPRAS40), and reduced cell proliferation (Ki67). Biomarker modulation 
was also observed at lower capivasertib doses of 240 and 360 mg bid, and the inhibitory 
effects were dose and concentration dependent. Overall, the STAKT study provides 
further evidence that capivasertib has the potential to be an effective oral anticancer 
therapy via its impact on proliferative AKT signaling in patients with estrogen-receptor-
positive breast cancer. 
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Abstract  
Purpose: The STAKT study examined short-term exposure (4.5 days) to oral selective 
pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its 
therapeutic target in sufficient concentration to significantly modulate key biomarkers of 
the AKT pathway and tumor proliferation. 
 
Methods: STAKT was a two-stage, double-blind, randomized, placebo-controlled, 
‘window-of-opportunity’ study in patients with newly diagnosed ER+ invasive breast 
cancer. Stage 1 assessed capivasertib 480 mg bid (recommended monotherapy dose) 
and placebo, and stage 2 assessed capivasertib 360 and 240 mg bid. Primary 
endpoints were changes from baseline in AKT pathway markers pPRAS40, pGSK3β 
and proliferation protein Ki67. Pharmacologic and pharmacodynamic properties were 
analyzed from blood sampling, and tolerability by adverse-event monitoring. 
 
Results: After 4.5 days’ exposure, capivasertib 480 mg bid (n=17) produced significant 
decreases from baseline versus placebo (n=11) in pGSK3β (H-score absolute change  
–55.3, P=0.006) and pPRAS40 (–83.8, P<0.0001), and a decrease in Ki67 (absolute 
change in percentage positive nuclei: –9.6%, P=0.031). Significant changes also 
occurred in secondary signaling biomarker pS6 (–42.3, P=0.004), while pAKT (and 
nuclear FOXO3a) also increased in accordance with capivasertib’s mechanism (pAKT: 
81.3, P=0.005). At doses of 360 mg bid (n=5) and 240 mg bid (n=6), changes in primary 
and secondary biomarkers were also observed, albeit of smaller magnitude. Biomarker 
modulation was dose and concentration dependent, and no new safety signals were 
evident. 
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Conclusions: Capivasertib 480 mg bid rapidly modulates key biomarkers of the AKT 
pathway and decreases proliferation marker Ki67, suggesting future potential as an 
effective therapy in AKT-dependent breast cancers. 
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Introduction 
Components of the AKT pathway (also known as the PI3K/AKT/mTOR signaling 
pathway) play a fundamental role in tumor cell survival, proliferation and death 
(Supplementary Figure 1) (1). Mutations in signaling components can cause aberrant 
activation of the pathway, leading to the development of numerous solid and 
hematologic malignancies (1-3) and resistance to endocrine therapies (4, 5). Mutations 
in PIK3CA, AKT1 and PTEN are prevalent in estrogen-receptor-positive (ER+) breast 
cancer (6), indicating that this pathway is important in ER+ breast cancer, which is 
further augmented by the observation of a reciprocal feedback between the ER and 
PI3K/AKT signaling pathways. 
 
Capivasertib (AZD5363) is a new oral selective AKT1–3 inhibitor that demonstrated 
promising clinical activity and a tolerable safety profile as monotherapy treatment in a 
Phase I study in heavily pre-treated (median of five prior regimens) patients with AKT1 
E17K mutant metastatic solid cancers, with the strongest signal of activity observed in 
ER+ breast cancers (7). In cancer model systems, the inhibitor blocks the AKT pathway, 
depleting phosphorylation of pathway proteins GSK3β, PRAS40, and S6 and tumor cell 
growth (8). In preclinical experiments, reductions of 50–80% in phosphorylated PRAS40 
(pPRAS40) and 40–70% in pGSK3β during the capivasertib dosing period were 
sufficient to cause significant antitumor activity in several xenograft models (eg 100 
mg/kg twice daily [bid] in the BT474c xenograft model) (8). For Ki67, information was 
drawn from two previous pre-surgical studies of endocrine therapy in ER+ breast cancer 
(9, 10). The change in Ki67 in one of these, an endocrine study (NCT00259090), was a 
>80% decrease in all treated groups with clear statistical significance (10). 
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Successful drug development is critically dependent on an understanding of drug 
pharmacodynamics, including knowledge of the drug’s rapidity of action and effect on 
molecular treatment targets. In this regard, the STAKT trial (NCT02077569) is the first 
two-stage, pre-surgical, window-of-opportunity biomarker study to focus on assessing 
the effects of a range of capivasertib monotherapy doses on key markers of the AKT 
pathway and expression of a protein strongly associated with tumor cell proliferation and 
growth (Ki67) in patients with newly diagnosed ER+ breast cancer. These markers were 
used to characterize the degree of biological activity and, thus, treatment potential in 
primary breast cancer arising from the inhibition of AKT signaling across a range of 
capivasertib doses.  
 
The STAKT study aimed to help define the optimal dose of capivasertib for future 
studies, as well as aid further understanding of its impact on the AKT pathway and 
biomarker identification. Stage 1 of the study assessed the pharmacodynamic (PD) and 
pharmacokinetic (PK) effect and tolerability of capivasertib 480 mg bid versus placebo. 
Stage 2 examined the same, but at lower doses (320 and 240 mg bid) of capivasertib. It 
was hoped that exploring a range of doses in the study would also enable predictive 
model-based techniques to be developed to help identify an efficacious dosing range 
and dose reduction strategies for potential use in future stages of clinical development in 
breast cancer.  
 
Here, data are presented from STAKT stages 1 and 2 that reveal the targeted effect of 
capivasertib on selected tumor and cell proliferation biomarkers, the PD properties of the 
dose– and exposure–response relationship, and tolerability from short-term exposure in 
patients with breast cancer.  
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Patients and methods 
Key eligibility criteria 
Eligible patients were females aged ≥18 years with histologic confirmation of ER+ 
invasive breast carcinoma (stage 1–3 or stage 4 breast cancer with primary tumor in the 
breast amenable to biopsies) and tumors large enough to provide tissue for the 
biomarker assays. Additional key eligibility criteria included: subsequent standard of care 
determined to include chemotherapy, with or without surgery (as such treatment was 
considered to carry a greater risk of genotoxicity compared with exposure to 
capivasertib); WHO performance status 0–1 with no deterioration over the previous 2 
weeks; and hepatic, renal, cardiac, lung and gastrointestinal functions within normal 
limits, except if liver metastases were present, in which case liver enzyme levels could 
be up to three times the upper limit of normal. To reduce the potential risk of the drug 
exacerbating abnormal glucose profiles (11), patients with type 1 or 2 diabetes mellitus 
(irrespective of management), fasting glucose ≥7 mmol/L or glycated hemoglobin 
(HbA1c) ≥64 mmol/mol or ≥8% at screening were excluded from participating in this 
study. Patients had no known history of hypersensitivity to the active ingredient or 
inactive excipients of capivasertib. 
 
Study conduct 
All patients provided written informed consent. The National Research Ethics Service 
Committee East Midlands – Northampton Research Ethics Commitee (REC) approved 
the protocol. The STAKT study (trial registration ID: NCT02077569; REC ID: 
13/EM/0112; Clinical Trial Authorization reference: 03057/0057/001) had local National 
Health Service (NHS) R&D approval and was conducted in accordance with the 
Declaration of Helsinki, Good Clinical Practice and the Department of Health Research 
Governance Framework for Health and Social Care 2005. The study was also performed 
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in accordance with the Cancer Research UK Guidelines for Scientific Conduct (12). An 
independent data monitoring committee (IDMC) reviewed emerging data and, in 
particular, the results of stage 1 to approve the continuation of the study into stage 2. 
Trial oversight was provided by an independent trial steering committee on behalf of the 
funders and sponsors. The trial management group was responsible for the running of 
the trial. Tayside Clinical Trials Unit was responsible for the day-to-day management of 
the trial and undertook the data analyses in accordance with the statistical analysis plan 
for the study. 
 
Study design and treatment 
STAKT was a multicenter, two-stage, double-blind, randomized, placebo-controlled, 
paired-biopsy, biomarker study conducted in NHS hospitals throughout the UK. The two-
stage study format was designed to obtain early evidence that the drug is 
pharmacokinetically and pharmacodynamically active at the 480 mg bid dose, which, 
based on initial tolerability, PK and preliminary efficacy data from a previous Phase I 
study (NCT01226316) (13), was the most likely dose and schedule to be used in clinical 
studies. 
 
In stage 1, eligible patients were randomized (1:1) to either capivasertib 480 mg bid or 
placebo for 4.5 days. In stage 2, patients were randomized (1:1) to capivasertib 360 or 
240 mg bid for 4.5 days (Supplementary Figure 2). Enrollment in stage 2 was planned to 
commence seamlessly upon completion of stage 1, dependent on, in the opinion of the 
IDMC, the 480 mg bid dose producing a depletion to a pre-specified margin of ≥50% 
over placebo for the primary biomarkers pPRAS40, pGSK3β (both key indicators of AKT 
signaling) and Ki67. In fact, there was a short break in patient recruitment between 
stages 1 and 2, supported by the study IDMC, as the study team made the decision to 
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remove an originally planned placebo arm for stage 2 (protocol amendment approved by 
the REC and the Medicines and Healthcare Products Regulatory Agency in December 
2015) because of unforeseen recruitment challenges. Changes in the lower doses of 
capivasertib were then assessed against baseline rather than placebo.  
 
Patients received capivasertib for 4.5 days prior to their scheduled surgery or 6.5 days 
prior to scheduled chemotherapy (the final morning dose was taken on the day of 
surgery, which accounts for the final 0.5-day period). Ultrasound-guided tumor core 
biopsies were taken prior to the first dose and after 4.5 days of dosing (within 12 hours 
after the last dose). Additional ‘triple blinding’ was performed by blinding laboratory staff 
to treatment arm and time of biopsy (baseline or after 4.5 days). Biopsy samples were 
formalin fixed and paraffin embedded and immunohistochemically stained using the pre-
validated assays detailed in Supplementary Table 1, and tumor epithelial staining was 
assessed by H-scoring the primary biomarkers pGSK3B and pPRAS40 by consensus of 
two expert assessors. H-score was calculated as the sum, (% weak [1+]) + (% moderate 
[2+] x 2) + (% strong [3+] x 3), of staining localized in the cytoplasm and/or nucleus. Ki67 
was evaluated by percentage nuclear positivity only. Biopsy pairs were sectioned 
together and analyzed in the same immunostaining assay, with a positive internal control 
included in every assay for quality control purposes. Blood samples for PK were 
scheduled at: pre-dose; 2, 4, and optional 6 and 8 hours after the first dose on day 1; 
and after the last dose on day 5, as close to the time of the on-treatment biopsy as 
possible. 
 
Study objectives 
The primary objective of STAKT was to compare the AKT pathway biomarker and 
antiproliferative effect of 4.5 days’ treatment with three dose levels of capivasertib. 
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Primary endpoints were changes from baseline for the active phosphorylated forms of 
the selected primary biomarkers, pPRAS40 and pGSK3β, and Ki67. Secondary 
endpoints included changes in additional biological markers associated with the AKT 
pathway, comprising tumor epithelial staining for pAKT (cytoplasmic/nuclear/membrane), 
phosphorylated ribosomal protein S6 (cytoplasmic) and FOXO3a expression (nuclear 
and/or cytoplasmic), as well as an assessment of tolerability through monitoring of 
adverse events (AEs) with Common Terminology Criteria for Adverse Events (CTCAE) 
version 4 (graded as mild, moderate or severe). Additionally, relationships between 
primary biomarkers and capivasertib exposure (dose and plasma concentration) were 
explored post hoc to help identify a dosing range for potential use in later clinical 
development.  
 
Statistical design 
Up to 60 patients were planned to be recruited in each of stages 1 and 2. Twelve 
patients per arm with evaluable biomarker data would give 98% power to detect a 
difference of 30% (change from baseline) for pPRAS40 and pGSK3β levels between the 
treatment arms, at the 5% significance level. Assumptions for Ki67 in this study were for 
80% power and a two-sided significance level of 5%. With 12 evaluable patients, the 
study would be powered to show a 50% reduction in Ki67.  
 
Statistical analysis methods 
The biomarker population consisted of all patients with evaluable biomarker data at 
baseline and evaluable pre- and on-treatment biopsies. Evaluable patients were defined 
as having both pre- and on-treatment biopsy samples with a minimum of 100 tumor 
epithelial cells for H-score assessment for both pGSK3β and pPRAS40, as well as a 
minimum of 500 tumor epithelial cells to count for percentage positivity for Ki67. In 
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addition, the tumor had to express all three primary endpoint biomarkers in the pre-
treatment biopsy (defined as measureable percentage positivity for Ki67 nuclear staining 
[any score greater than zero is acceptable] and a total H-score, ie cytoplasm + nuclear, 
of ≥10 for each of pPRAS40 and pGSK3b), and patients also should have received the 
full planned 4.5-day dose of capivasertib treatment.  
 
An analysis-of-covariance model was fitted to the biomarker data, including terms for 
treatment and adjusting for baseline biomarker level. For each biomarker, changes in 
expression between the matched baseline and on-treatment biopsies were evaluated 
and compared with changes seen in the placebo group (comparison with placebo in 
stage 1 only). Both absolute and percentage changes from baseline were recorded. 
Stage 2 comparisons were against baseline biomarker level. The strength and direction 
of association between biomarkers were assessed by Spearman’s rank correlation 
coefficient. 
 
Dose– and exposure–response relationships were compared for three exposure 
variables: dose level given (ie 240 mg bid, as opposed to the total daily dose of 480 mg 
per day); observed maximum capivasertib plasma concentration (Cmax) on day 1; and 
capivasertib plasma concentration on day 5. Linear and Emax models were compared for 
each exposure variable, and the Akaike information criterion was used as a goodness-
of-fit diagnostic (14). 
 
The safety population consisted of all patients receiving ≥1 dose of study drug and was 
assessed by the incidence and severity of treatment-emergent adverse events (TEAEs) 
reported within 7 days following the first dosing of capivasertib, or up to the time of start 
of chemotherapy if earlier.  
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Results 
Patient disposition 
In total, 36 patients from 12 participating hospitals were randomized in stage 1 (19 
patients to capivasertib 480 mg bid, 17 patients to placebo), and 12 patients in stage 2 
(7 patients to capivasertib 240 mg bid, 5 patients to capivasertib 360 mg bid). All 48 
randomized patients (36 patients from stage 1, 12 patients from stage 2) received at 
least one dose of study treatment and were evaluable for safety analysis. Eight patients 
were deemed not evaluable for biomarker analysis in stage 1. All patients were deemed 
evaluable in stage 2, giving a total evaluable biomarker population of 40 patients.  
 
Of the seven patients randomized to capivasertib 240 mg bid in stage 2, one was 
subsequently found not to meet the pre-specified eligibility criterion of a total H-score of 
≥10 for pGSK3β (total score was 6) and pPRAS40 (total score was 5) staining in the pre-
treatment sample. This was identified after the stage 2 data lock; hence, this patient was 
excluded from the biomarker analysis. Therefore, a final total of 39 patients were 
evaluable in the biomarker population (28 patients from stage 1, 11 patients from stage 
2) according to the pre-defined evaluability criteria. No notable differences between the 
baseline characteristics in the patient populations enrolled across stages 1 and 2 were 
discerned (Table 1). 
 
Changes in biomarkers 
Significant reductions in the absolute change measurements in H-score for the primary 
biomarkers were observed for the 480 mg bid dose versus placebo: –55.3 (P=0.006) for 
total pGSK3β and –83.8 (P<0.0001) for total pPRAS40 (Table 2). The absolute 
percentage reduction in nuclei staining positive for Ki67 was also significant, at –9.6 
(P=0.031). The percentage change from baseline at the 480 mg bid dose versus 
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placebo was also significant for total pGSK3β (–39% [P=0.006]) and total pPRAS40 (–
50% [P<0.0001]). Reductions from baseline (absolute and percentage) were also 
observed for pGSK3β and pPRAS40 at the 360 mg bid and 240 mg bid doses. The 
secondary biomarkers pAKT and pS6 also showed significant change from baseline in 
H-score for the 480 mg bid dose versus placebo, but FOXO3a did not (Table 2). 
 
However, when the contribution to total H-score from cytoplasmic staining was 
separated from nuclear staining for the biomarkers whose total H-scores were derived 
from nuclear plus cytoplasmic staining (pGSK3β, pPRAS40, pAKT and FOXO3a), it was 
noted that FOXO3a showed a significant decrease in cytoplasmic H-score (absolute 
change –46.2, P<0.0001 vs placebo), while there was a corresponding substantial 
increase in nuclear H-score for this marker (absolute change 79.3, P=0.0009 vs 
placebo) at the 480 mg dose level. Such a difference in staining profile for different 
cellular compartments was not observed for the other biomarkers (Table 2). 
 
An immunohistochemistry assay for cleaved caspase-3, as a measure of apoptosis, was 
additionally performed, and the percentage positivity was gauged in a total population of 
500 and, where possible, 3000 tumor cells. Absolute and percentage changes were 
assessed by analysis of variance (ANOVA) adjusted for treatment and baseline values. 
Only one of eight ANOVA analyses (considering percentage apoptosis in 3000 cells 
adjusted for baseline) gave a P value of <0.05 (data not shown).  
 
A ‘heat map’ showing the changes in the primary and secondary biomarkers for each 
patient in the three capivasertib groups, as well as the placebo group, is shown in Figure 
1a. Compared with placebo, more substantial and frequent decreases were seen with 
the 480 mg dose for Ki67 and the AKT pathway markers pGSK3β, pPRAS40 and pS6, 
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with 13/17 patients showing some change in all three primary biomarkers. Increases in 
turn were more common with such treatment for pAKT (12/17 patients) and nuclear 
FOXO3a expression (13/17 patients). At doses of 360 and 240 mg bid, declines in the 
biomarkers pGSK3β, pPRAS40 and pS6 were also observed, albeit of smaller 
magnitude for the primary markers than seen with the 480 mg dose (particularly for Ki67; 
Table 2). Increases were again noted for pAKT and nuclear FOXO3a. Representative 
immunohistochemistry staining images for both primary and secondary biomarkers at 
baseline and on treatment can also be seen in Figure 1b, showing declines in Ki67, 
pGSK3B, pPRAS40 and pS6, and increases in pAKT and nuclear FOXO3a, with the 480 
mg dose that are not apparent with placebo. 
 
Correlation coefficient analyses 
A correlation coefficient analysis (Spearman’s rank) of the percentage changes in 
biomarkers at the 480 mg bid dose (Figure 2) indicated significant positive correlation 
between changes in pGSK3β (total) and Ki67 (nuclear) (R=0.52, P=0.031), and between 
pGSK3β (total) and pS6 (cytoplasmic) (R=0.54, P=0.025). Negative correlations were 
determined between FOXO3a (nuclear) and Ki67 (nuclear) (R=0.75, P<0.0001), 
FOXO3a (nuclear) and pGSK3β (R=0.71, P=0.0014), and FOXO3a (nuclear) and pS6 
(R=0.61, P=0.0092). These correlations observed at the 480 mg bid dose were not 
replicated in the placebo group (Figure 2). Correlation coefficients for the lower doses 
were not robust, most likely because of the small patient numbers in these groups, 
although a reduced PD effect cannot be ruled out. 
 
Pharmacokinetics 
The capivasertib Cmax was generally observed 2 hours post-dose. There was a trend 
towards increasing Cmax and concentration on day 5 with increasing dose (Figure 3). The 
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variation in concentration on day 5 is influenced by the variability in sampling times, 
which is noted in the discussion. 
 
Dose– and exposure–response relationships 
Biomarker modulation was dose and concentration dependent. The dose–response 
relationship for percentage change from baseline could be described by a non-linear 
(Emax) model for all primary biomarkers (Figure 4). Similar correlations were observed for 
the change in the biomarkers and PK exposure (Cmax on day 1 or concentration at the 
time of biopsy on day 5). 
 
Tolerability 
In total, 78 TEAEs (ie within 7 days of first dosing or before scheduled chemotherapy) 
were reported in 27 of 31 (87%) patients receiving capivasertib (all doses), and 23 
TEAEs in 10 of 17 (59%) patients receiving placebo (Table 3). Among the 27 patients 
receiving capivasertib (all doses) and reported to have a TEAE (all grades – mild, 
moderate or severe), diarrhea was observed most frequently, with 13 (17%) events out 
of a total of 78, followed by nausea with eight events out of 78 (10%).  
 
One patient (1.7%) receiving capivasertib 480 mg was reported to have a decreased 
ejection fraction. No hyperglycemic TEAEs were reported in the capivasertib-treated 
patients. Three patients had an AE assessed by the investigator as ‘possibly’ causally 
related to the study drug (one in each patient): 480 mg bid, atypical migraine; 360 mg 
bid, neutropenia; and 240 mg bid, neutropenia. All three patients subsequently 
recovered from the AE. 
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Three treatment-emergent serious adverse events (SAEs) were recorded at the  
480 mg bid dose (delayed recovery from anesthesia, nausea, vomiting) and two at the 
340 mg bid dose (dizziness, nausea). No SAEs were recorded in the 240 mg bid or 
placebo groups. No patients discontinued capivasertib (any dose) because of an AE.
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Discussion 
Window-of-opportunity studies performed in the time between diagnosis and standard-
of-care treatment, in which patients are briefly exposed to an investigative compound, 
can facilitate early understanding of the PD and dose/exposure–response effects of a 
drug and may confirm identification of predictive response markers for retrospective 
analyses of ongoing or completed clinical trials (15). Equally, such studies provide a 
unique opportunity to monitor drug mechanism in vivo, including providing evidence of 
hit on the target pathway and its important cellular endpoints. 
 
The principal research questions addressed in the STAKT study reported here were 
whether the new selective pan-AKT inhibitor capivasertib, particularly at the 
recommended monotherapy dose of 480 mg bid, could reach its therapeutic target AKT 
pathway in primary breast cancer patients, and if so, whether this was to the extent 
necessary to produce anticancer efficacy; these were assessed by the effects on 
markers indicative of functional AKT signaling and tumor proliferation, respectively. Our 
results show that capivasertib 480 mg bid, after 4.5 days of treatment, does indeed 
reach its therapeutic AKT pathway target in such patients, as evidenced by statistically 
significant decreases from baseline compared with placebo in activity (phosphorylation) 
of the pathway biomarkers GSK3β and PRAS40, as well as pS6, accompanied by 
significant decreases in tumor Ki67 (Table 2). Pathway biomarker modulation was also 
observed at the lower doses of 240 and 360 mg bid, albeit generally to a lesser degree, 
indicating that the inhibitory effects of capivasertib were dose and concentration 
dependent. 
 
A heat map of the degree of biomarker modulation (Figure 1) further revealed that most 
patients receiving capivasertib 480 mg bid showed a reduction from baseline in the 
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primary biomarkers pGSK3β and pPRAS40, as well as in Ki67, and a (high) degree of 
correlation in the modulation of biomarkers within the same patient. By comparison, in 
the placebo group, changes were smaller in magnitude and more randomly distributed 
between increases and decreases, indicating no direct, substantive effects in the 
placebo group, contrasting with capivasertib, which was having a targeted modulating 
effect across multiple biomarkers in the AKT pathway. At the 480 mg bid dose, the heat 
map showed that marked primary biomarker changes were often seen in the same 
individuals, as opposed to the placebo group, in which such changes tended to be 
spread across several patients. Correlations between changes in pGSK3β and pS6, and 
between pGSK3β and Ki67, were identified for the 480 mg bid dose that were further 
suggestive of pathway element interplay, its impact on proliferation, and its targeting by 
capivasertib. Also, in all the capivasertib-treated groups, changes in multiple primary 
and/or secondary endpoint signaling pathway markers were seen in the majority of 
individuals. In total, these observations are indicative of capivasertib reaching its 
intended target as a controlled ‘hit’ down the whole AKT pathway in breast cancers. At 
doses of 360 and 240 mg bid, similar observations can be made to those at 480 mg, 
albeit of smaller magnitude for the primary markers (particularly for Ki67, whereby 
decreases were also less frequent), again suggesting that after 4.5 days’ dosing, 
capivasertib was reaching its intended signaling pathway target in a consistent manner. 
 
The secondary biomarkers analyzed (pAKT, pS6 and FOXO3a) also showed significant 
changes in this study that are consistent with inhibition of the AKT pathway. The 
observed induction of pAKT is consistent with previous preclinical and clinical data; 
capivasertib increases phosphorylation of AKT itself, and it has been reported that this is 
due to the protein being held in a hyperphosphorylated but catalytically inactive form as 
a consequence of compound binding (8, 13, 16). Results were obtained from paired 
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biopsies collected during two previous Phase I studies (NCT01226316 and 
NCT01353781), albeit in metastatic solid malignancies (including those with PIK3CA 
mutation). These Phase I studies also showed downregulation of PD biomarkers (eg 
pPRAS40 and pGSK3b) following capivasertib treatment, increased phosphorylation 
levels of AKT (consistent with ATP competitive mechanism of action), and inhibition of 
FOXO nuclear translocation (13, 17).  
 
In contrast to these Phase I studies, the STAKT study was more controlled, ie paired 
samples were collected at similar time points and from patients with similar disease and 
a placebo control group was included. The STAKT study results we report are consistent 
with the data from the Phase I studies and demonstrate the PD effects more robustly 
and for the first time in primary breast cancers. For FOXO3a, the large decrease in 
cytoplasmic staining and corresponding large increase in nuclear staining after 4.5 days’ 
exposure seems likely to be a result of redistribution of FOXO3a within the cancer cell as 
a consequence of upstream changes in AKT signaling pathway activity. This is 
consistent with the data in paired biopsies from solid tumors in the capivasertib Phase I 
study (13) and validates the preclinical observation of induction of nuclear accumulation 
of FOXO3a in BT474c breast cancer cells (HER2 amplified PIK3CA mutant) exposed to 
capivasertib (18). It has been reported that AKT-pathway-driven phosphorylation of 
FOXO3a is arrested by AKT inhibition (18), permitting translocation of FOXO3a to the 
nucleus; in keeping with this, inverse associations were seen in our study between 
changes in nuclear FOXO3a and the pathway signaling markers pGSK3β and pS6. 
Once inside the nucleus, as a transcription factor, FOXO3a is able to initiate expression 
of the tumor suppressive genes BIM, FasL and p27, which collectively can induce cell 
cycle arrest and so may contribute to proliferation inhibition with the drug and/or 
apoptosis (18). The effect of capivasertib on such tumor proliferation, within the 
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treatment window of 4.5 days, is clearly seen in the Ki67 results here, and changes in 
nuclear FOXO3A with 480 mg dose also showed an indirect correlation with changes in 
Ki67. The impact of the drug on apoptosis, whereby cell survival can be a further 
consequence of AKT signal transduction, has not been clearly shown within the short 
time frame of the STAKT study by the cleaved caspase-3 staining results. Future 
translational studies should look to address this question. 
 
Peak plasma concentration for capivasertib was generally observed 2 hours post-dose, 
and there was a trend towards increasing Cmax and concentration on day 5 with 
increasing dose. Variability in time of sampling after dose caused variation in day 5 
concentrations between patients that contributed to the large overlap noted between 
dose groups (Figure 3). The PK data reported here are consistent with the emerging PK 
profile for capivasertib that indicates a median time to Cmax of 2 hours (range 0.5–6 
hours), with a terminal half-life of approximately 10 hours (range 7–15 hours) after the 
first dose (11, 13, 17). Weak dose–response relationships (percentage change from 
baseline) were identified for the two primary biomarkers (pGSK3β and pPRAS40) and 
Ki67. Generally, the correlation between the primary biomarkers and PK exposure was 
similar to the correlation with dose.  
 
The safety profile of capivasertib was previously reported, and the most frequently 
reported side effects are gastrointestinal events (diarrhea, vomiting, nausea), fatigue, 
hyperglycemia and maculopapular rash (7, 11, 13). The safety assessment of 
capivasertib in the STAKT study reported was, by nature of a window-of-opportunity 
study, short in comparison with prior and ongoing studies of the compound. The TEAEs 
and SAEs observed in STAKT were as previously reported for capivasertib, and no new 
safety signals became evident. 
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Since the STAKT trial was completed, the Phase II study (PAKT – NCT02423603) has 
reported improved progression-free survival (PFS) and overall survival (OS) from the 
combination of capivasertib and paclitaxel as first-line therapy in patients with triple-
negative breast cancer; an enhanced effect on PFS was observed in patients with 
mutations in the PIK3CA, AKT1 or PTEN genes (19). More recently, in a Phase II, 
randomized, double-blind, placebo-controlled study (FAKTION (20) – NCT01992952), 
capivasertib in combination with fulvestrant significantly improved PFS in patients with 
advanced ER+ human epidermal growth factor receptor 2 negative (HER2–) breast 
cancer previously treated with aromatase inhibitors, with an observed OS improvement 
of approximately 6 months, although this was not statistically significant (37% OS data 
maturity). The successful development of a targeted AKT inhibitor such as capivasertib, 
either as monotherapy or in combination, may provide a new treatment option in breast 
cancer that helps circumvent endocrine therapy resistance from aberrant activation of 
the pathway (21). In a separate Phase II trial (BEECH – NCT01625286), adding 
capivasertib to weekly paclitaxel did not prolong PFS in a population of patients with 
advanced ER+/HER2− breast cancer or in a subpopulation whose tumors harbored a 
PIK3CA mutation (22). Notably, no concomitant endocrine therapy was permitted during 
the BEECH study. The STAKT translational study, with the PK/PD data showing that 
capivasertib is able to reach its therapeutic target in sufficient concentration to 
significantly modulate key biomarkers of the AKT pathway and tumor proliferation, 
provides biological support for the improved clinical outcomes seen in a likewise 
hormone-receptor-positive tumor population in the FAKTION trial.   
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Study limitations 
The small sample size in stage 2, from unforeseen recruitment challenges, was 
mitigated by scientific rationale endorsed by ethical approval to withdraw the placebo 
arm in stage 2: it was agreed that assessment of dose-related effects could be achieved 
by comparing on-treatment PD results with baseline in the three dose groups, and that 
the placebo arm in stage 2 could be dropped. Biomarker changes after 4.5 days were 
therefore assessed against baseline biomarker levels in stage 2. This was different from 
stage 1, in which changes in biomarkers were compared with changes in the placebo 
arm. The reduced patient numbers in stage 2 also meant that robust statistical analyses 
of biomarker expression between the three doses was not possible. A second limitation 
was that the mutational status of these tumors was not assessed; therefore, it is not 
clear at this time whether the extent of the PD effect of capivasertib monotherapy is 
associated with alterations in key genes of the pathway (ie PIK3CA/AKT1/PTEN). This 
warrants further investigation. 
 
 
Conclusions 
The STAKT study has shown that capivasertib causes dose- and concentration-
dependent effects on primary endpoint markers of its target AKT pathway (pGSK3β and 
pPRAS40) and the proliferation marker, Ki67, after only 4.5 days’ exposure. To our 
knowledge, this is the first such study with this drug in primary breast cancer and is also 
the shortest pre-surgical window-of-opportunity study in breast cancer to show a 
significant decrease in tumor proliferation with a targeted therapy, which also exemplifies 
the effectiveness of such studies for investigating novel potential treatment compounds. 
Changes in secondary markers in the pathway (eg pAKT, FOXO3a and pS6) were also 
in accordance with the drug targeting this pathway. Correlations between a number of 
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tumor biomarkers were identified for capivasertib 480 mg bid (13). These correlations 
were in keeping with the drug’s expected mechanism of inhibitory impact on the AKT 
signaling pathway, as were changes in the primary and secondary endpoints. Biomarker 
modulation was also observed at the lower capivasertib doses of 240 and 360 mg bid, 
although statistical analysis was limited by the small sample size at the lower doses. 
 
The data presented confirm that capivasertib at the recommended monotherapy dose 
(480 mg bid) rapidly modulates the AKT pathway, and the significant resultant decrease 
in tumor Ki67 also raises the potential that it may be an effective anticancer therapy in 
AKT-dependent breast cancers. These findings, together with the positive results in the 
Phase II randomized trial FAKTION, support further development of capivasertib in 
patients with hormone-receptor-positive metastatic breast cancer. 
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Tables 
Table 1. Characteristics of patients at study entry (biomarker analysis set) 
 Stage 1 Stage 2 
Clinical characteristics Placebo 
 
(n=11) 
Capivasertib  
480 mg bid 
(n=17)
a
 
Capivasertib  
360 mg bid 
(n=5) 
Capivasertib  
240 mg bid 
(n=6)
b
 
Mean age, years (SD) 48.5 (7.2) 51.3 (9.6) 52.6 (12.9) 58.5 (11.1) 
Mean BMI, kg/m
2
 (SD) 27.3 (6.6) 28.8 (4.9) 31.5 (4.1) 27.4 (4.5) 
Mean weight, kg (SD) 75.6 (17.9) 78 (12.9) 86.2 (11.4) 72.7 (9.4) 
Mean height, m (SD) 1.7 (0.07) 1.7 (0.05) 1.7 (0.03) 1.6 (0.1) 
Ethnicity, n (%) 
White (Caucasian) 
Black (including 
Afro-Caribbean) 
 
10 (90.9) 
1 (9.1) 
 
17 (100) 
0 
 
5 (100) 
0 
 
6 (100) 
0 
a
Nineteen patients were randomized to capivasertib in stage 1, of whom 17 were evaluable for 
biological endpoints (two patients did not take all study medication and were therefore considered 
unevaluable for biological endpoints but were included in the safety analyses); 
b
Seven patients were 
randomized to capivasertib in stage 2 (240 mg bid group) and included in the primary analysis. One 
patient was subsequently found not to meet the pre-specified eligibility criterion of a total H-score of 
≥10 for pPRAS40 (total score was 5) and pGSK3β (total score was 6). BMI, body mass index; SD, 
standard deviation 
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Table 2. Analysis of change from baseline for the primary and secondary 
biomarkers 
A) 480 mg bid versus placebo (stage 1) 
  Capivasertib 
480 mg bid 
(n=17) 
Mean difference in change 
 between groups  
(mixed model)
a
 
  Type of change 
vs baseline 
Adjusted 
(95% CI)
b
 
P value vs 
placebo arm 
Primary  
   
Ki67 (% cells positive)    
 Nuclear Absolute –9.6 (–18.3, –0.98) 0.031 
  % –23.4 (–59.1, 0.29) 0.052 
pGSK3β (H-score)    
 Total Absolute –55.3 (–93.4, –17.7) 0.006 
  % –39.0 (–65.5, –12.5) 0.006 
 Cytoplasmic Absolute –53.6 (–90.5, –16.8) 0.006 
  % –39.2 (–65.8, –12.7) 0.006 
 Nuclear Absolute –2.8 (–5.9, 0.19) 0.065 
  % –36.5 (–74.4, 1.35) 0.058 
pPRAS40 (H-score)    
 Total Absolute –83.8 (–111.6, –56.0) <0.0001 
  % –50.2 (–68.7, –31.7) <0.0001 
 Cytoplasmic Absolute –90.1 (–120.9, –9.3) <0.0001 
  % –55.8 (–75.4, –36.2) <0.0001 
 Nuclear Absolute 6.9 (–10.7, 24.6) 0.42 
  % 8.9 (–258.2, 276.2) 0.94 
Secondary 
 
pAKT (H-score)    
 Total Absolute 81.3 (27.1, 135.5) 0.005 
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  % 116.9 (29.3, 204.6) 0.011 
 Cytoplasmic Absolute 24.8 (–7.51, 57.1) 0.127 
  % 76 (–3.3, 155.2) 0.0595 
 Nuclear Absolute 53 (13.2, 92.8) 0.011 
  % 516.5 (–29.7, 1062.6) 0.063 
pS6 (H-score)    
 Cytoplasmic Absolute –42.3 (69.7, –14.8) 0.004 
  % –30 (–48.8, –11.1) 0.003 
FOXO3a (H-score)    
 Total Absolute 29.6 (–19.9, 79.2) 0.229 
  % 19.4 (–21.4, 60.2) 0.338 
 Cytoplasmic Absolute –46.2 (–77.0, –15.4) <0.0001 
  % –42.4 (–97.2, 12.5) 0.124 
 Nuclear Absolute 79.3 (35.8, 122.8) 0.0009 
  % 843.5 (155.5, 1531.5) 0.018 
a
Mixed model: difference between placebo (n=11) and capivasertib (n=17) corrected for baseline 
values; 
b
Adjusted for baseline value 
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B) Mean change from baseline for all doses of capivasertib (stages 1 and 2) 
  Mean change from baseline (95% CI) 
  
Capivasertib  
480 mg bid 
(n=17) 
Capivasertib  
360 mg bid 
(n=5) 
Capivasertib  
240 mg bid 
(n=7) 
Primary 
    
Ki67 (% cells positive) 
   
Nuclear Absolute  –12.4 (–18.9, –5.92) 0.92 (–7.54, 9.38) 0.2 (–9.0, 9.3) 
 
% –38.3 (–57.6, –19.1) –0.33 (–30.3, 29.6) 21.6 (–15.7, 58.8) 
pGSK3β (H-score) 
   
Total 
Absolute –66.9 (–96.3, –37.6) –18.6 (–47. 8, 10.6) –39.2 (–98.9, 20.6) 
% –41.6 (–57.5, –25.8) –27.1(–74.2, 20.0) –9.30 (–94.9, 76.4) 
Cytoplasmic Absolute –62.4 (–89.4, –35.3) –18.6 (–47.8, 10.6) –21.57 (–86.1, 43.0) 
 
% –40.7 (–56.5, –25.0) –27.1 (–74.2, 19.9) 192.0 (–305.4, 689.5) 
Nuclear Absolute –4.6 (–10.9, –1.73) 0 0.14 (–0.21, 0.49) 
 
% –37.1 (–61.3, –12.8) 0 0 
pPRAS40 (H-score) 
   Total Absolute  –71.3 (–93.9, –48.7) –69.6 (–11.2, –28.0) –43.8 (–94.0, 6.3) 
 
% –43.7 (–56.7, –30.7) – 44.9 (–81.7, –8.12) –28.3(–65.6, 8.9) 
Cytoplasmic Absolute  –76.5 (–103.3, –49.6) –71.0 (–114.6, 27.5) –35.3 (–94.1, 23.5) 
 
% –51.2 (–65.4, –37.0) –46.9 (–86.6, –7.29) 350.7 (–587.6, 1288.9) 
Nuclear Absolute  5.2 (–8.2, 18.5) 1.4 (–4.0, 6.78) 11.3 (–6.02, 28.6) 
 
% 105.6 (–42.2, 253.4) 200 (–546.4, 946.4) 340 (–405.2, 185.2) 
Secondary 
   
pAKT (H-score) 
   
Total Absolute  70.4 (23.2, 117.5) 79 (–5.7, 163.7) 106 (39.8, 172.2) 
 
% 107.0 (25.2, 188.9) 71.3 (–19.9, 162.4) 133.5 (21.8, 245.2) 
Cytoplasmic Absolute  24.82 (–0.7, 50.35) 26 (–17.99, 69.99) 54.3 (18.5, 90.1) 
 
% 69.7 (0.43, 139) 43.6 (–43.7, 130.9) 119 (–10.2, 227.8) 
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Nuclear Absolute  45.5 (12.0, 78.8) 28.4 (1.86, 54.9) 55.3 (6.8, 103.8) 
 
% 508.2 (44.9, 971.4) 918.8 (–747.4, 2584.9) 1173.9 (–81.7, 2429.5) 
pS6 (H-score) 
   
Cytoplasmic Absolute –63.1 (–81.5, –44.6) –51.8 (–92.0, –11.6) –66.4 (–107.3, –25.5) 
 
% –38.8 (–48.8, 28.9) –40.5 (–83.3, 2.3) –21.2 (–92.3, 49.8) 
FOXO3a (H-score) 
   
Total Absolute 4.18 (–30.0, 38.3) 6.0 (–24.2, 36.2) –21.4 (–74.1, 31.2) 
 
% 12.1 (–13.5, 37.6) –12.8 (–73.6, 47.9) –23.1 (–118.9, 72.6) 
Cytoplasmic Absolute –65.6 (–96.9, –34.3) 34.4 (–20.5, 89.3) 35.0 (–7.5, 77.5) 
 
% –40.2 (–76.4, –3.91) 144.9 (–218.0, 507.8) 145.3 (–54.7, 345.2) 
Nuclear Absolute 69.8 (27.9, 111.6) 34.4 (–20.5, 89.3) 35 (–7.47, 77.5) 
 
% 924.8 (307.9, 1541.7) 144.9 (–218.0, 507.8) 145.3 (–54.7, 345.2) 
CI, confidence interval  
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Table 3. Treatment-emergent adverse events (all grades) observed at a frequency 
of ≥2 events in any treatment arm within 7 days of first dosing (safety analysis set) 
 Stage 1 Stage 2 All  
capivasertib 
doses 
(n=31)  
Placebo 
(n=17) 
Capivasertib 
480 mg bid 
(n=19) 
Capivasertib 
360 mg bid 
(n=5) 
Capivasertib 
240 mg bid 
(n=7) 
Number of patients 
experiencing a TEAE,
a
 
n (%) 
10 (59) 15 (79) 5 (100) 7 (100) 27 (87) 
Total number of TEAEs 
observed,
a
 n 
23 58 11 9 78 
Number of TEAEs 
observed by preferred 
term, n (%)
b
 
     
Diarrhea 3 (13.0) 11 (19.0) 1 (9.0) 1 ( 11.1) 13 (16.7) 
Nausea 3 (13.0) 6 (10.3) 1 (9.0) 1 ( 11.1) 8 (10.3) 
Headache 0  4 (6.9) 0 0 4 (5.1) 
Dizziness 0  3 (5.2) 1 (9.0) 0 4 (5.1) 
Proteinuria 1 (4.3) 3 (5.2) 0 0 3 (3.8) 
Fatigue 1 (4.3) 2 (3.4) 0 1 ( 11.1) 3 (3.8) 
Vomiting 1 (4.3) 2 (3.4) 0 0 2 (2.6) 
Pain in extremity 0  2 (3.4) 0 0 2 (2.6) 
Seroma 0 0 2 (18.2) 0 2 (2.6) 
Constipation 2 (8.7) 1 (1.7) 0 0 1 (1.3) 
Stomatitis 2 (8.7) 0 0 0 0 
a
Treatment emergent is defined as occurring within 7 days of first dosing or before scheduled 
chemotherapy; 
b
Percentage per dose = (number of TEAEs by preferred term / total number of TEAEs 
observed) x 100  
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Figures 
Figure 1. A) Heat map for stages 1 and 2 showing changes in primary and 
secondary biomarkers by individual patient. B) Examples of 
immunohistochemistry staining images 
A) Green denotes a change in the direction expected with AKT pathway inhibition using capivasertib. 
Notably, capivasertib induces increases in pAKT because of its ATP competitive mechanism of 
action. Patients are ranked in this figure by percentage change in Ki67 (nuclear percentage positivity); 
bars and numbers represent percentage change from baseline (except for pAKT, where bars are 
capped at –100% and +100% change for presentation purposes). B) Original magnification of staining 
images was 20 x 
 
Figure 2. Scatter plot matrices comparing the percentage changes in primary and 
secondary biomarkers for capivasertib 480 mg bid and placebo  
Nuclear score: Ki67 and FOXO3a; total score: pGSK3β, pPRAS40 and pAKT; cytoplasmic score: 
pS6. Relationships between biomarkers are quantified by Spearman’s rank correlation coefficient (R) 
with P value. The red and blue solid lines represent the linear regression lines for capivasertib and 
placebo, respectively, and the red and blue zones represent 95% CI 
 
Figure 3. Relationship between A) capivasertib dose and Cmax on day 1 and  
B) capivasertib dose and capivasertib plasma concentration on day 5 at time of 
biopsy 
 
Figure 4. Observed and model-predicted dose– and exposure–response 
relationships for A) pGSK3β, B) pPRAS40 and C) Ki67 as percentage change from 
baseline  
Day 5 concentrations are at the time of biopsy 
 
 
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
AZD5363
FOXO3a
Placebo
pPRAS40
AZD5363 Placebo
B
a
s
e
lin
e
O
n
 t
re
a
tm
e
n
t
B
a
s
e
lin
e
O
n
 t
re
a
tm
e
n
t
P
ri
m
a
ry
 o
u
tc
o
m
e
s
B
A
AZD5363 Placebo
pS6
B
a
s
e
lin
e
O
n
 t
re
a
tm
e
n
t
pGSKβ
B
a
s
e
lin
e
O
n
 t
re
a
tm
e
n
t
AZD5363 Placebo
AZD5363 Placebo
pAKT
B
a
s
e
lin
e
O
n
 t
re
a
tm
e
n
t
Ki67
B
a
s
e
lin
e
O
n
 t
re
a
tm
e
n
t
AZD5363 Placebo
S
e
c
o
n
d
a
ry
 o
u
tc
o
m
e
s
Figure 1
11
20
49
–88
–39
–38
–20
–11
–8
–4
–3
–57
–10
21
22
–59
18
8
4
0
0
43
7
34
–2
30
–30
0
–5
–3
15
10
15
19
–23
–63
21
–55
8
–11
24
–5
50
100
–71
11
–25
3
–7
11
–23
3
0
28
–21
–24
0
–20
–3
0
0
0
5
–32
–40
15
–57
–24
–91
–80
–75
–74
–65
–63
–62
–58
–21
–20
–14
–6
9
16
33
–28
–17
4
4
35
–21
–2
10
16
49
77
–14
–24
–88
–71
–80
–38
–37
–45
1
–79
–13
–98
–37
–36
–22
–27
0
–83
–50
7
–7
–3
–70
–71
–59
–25
–57
–63
–35
–29
0
–67
–62
–90
–33
–6
–25
–22
–29
–50
–30
–43
–11
–91
–78
–39
–25
–40
–19
31
513
–9
–40
–18
199
67
200
67
442
43
58
–29
–18
23
148
150
25
171
80
–34
57
82
45
197
251
10
117
308
–53
–5
–39
–64
–47
–43
–32
–32
–38
–67
–41
–62
–58
–32
–30
–2
–13
–91
–61
–14
–11
–26
–52
–67
–41
–38
–33
–69
60
80
76
90
90
60
35
90
50
5
0
1
–20
55
–25
35
–10
54
0
10
0
15
–35
25
54
45
20
5
–58
–21
–28
–80
–19
150
P
la
c
e
b
o
Ki67 (nuclear staining)
Positive cells (%)
pGSK3b
Primary markers
Total H-score
pPRAS40
Total H-score
pAKT
Total H-score
pS6
Secondary markers
Cytoplasmic H-score
FOXO (nuclear staining)
Positive cells (%)
C
a
p
iv
a
s
e
rt
ib
4
8
0
 m
g
C
a
p
iv
a
s
e
rt
ib
3
6
0
 m
g
C
a
p
iv
a
s
e
rt
ib
2
4
0
 m
g
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
200
100
R=0.47, P=0.054
R=0.37, P=0.15
R=0.48, P=0.052 R=0.22, P=0.39
R=0.43, P=0.084
R=–0.27, P=0.29 R=–0.061, P=0.82
R=0.22, P=0.39
R=–0.61, P=0.0092
R=0.54, P=0.025
R=–0.71, P=0.0014
R=0.23, P=0.37
R=–0.0049, P=0.99
R=0.46, P=0.065
R=–0.75, P=0.0006
0
−100
−100
−50
0
50
100
150
1000
750
500
250
0
−250
−100
4000
2000
–2000
0
0
100
−100
−100 0 100 200
−100 0 100 200
0
Ki67 (%)
Ki67 (%)
Ki67 (%)
100 200
−100 0
Ki67 (%)
100 200
−100 0
Ki67(%)
p
G
S
K
3
β
p
P
R
A
S
4
0
−100
−50
0
50
100
150
−100 0
pGSK3β
100 200
p
P
R
A
S
4
0
−250
0
250
500
750
1000
−100 0
pGSK3β
100 200
p
A
K
T
−100
0
100
−100 0
pGSK3β
100 200
p
S
6
−2000
0
2000
4000
−100 0
pGSK3β
100 200
F
O
X
O
−250
0
250
500
750
1000
−100 0
pPRAS40
50−50 150100
p
A
K
T
−100
0
100
−100 0−50
pPRAS40
50 150100
p
S
6
–2000
0
2000
4000
−100 –50 0
pPRAS40
50 100 150
F
O
X
O
−100
0
100
−250 2500
pAKT
500 1000750
p
S
6
−2000
0
2000
4000
0 250
pAKT
500 750 1000
F
O
X
O
−2000
0
2000
4000
−100 0
pS6
100
F
O
X
O
p
A
K
T
p
S
6
F
O
X
O
100 200
PlaceboCapivasertib
R=0.59, P=0.057
R=0.19, P=0.57
R=0.33, P=0.32 R=0.33, P=0.32
R=0.31, P=0.35
R=–0.37, P=0.26 R=0.07, P=0.84
R=0.31, P=0.36
R=0.14, P=0.67
R=–0.041, P=0.9
R=0.12, P=0.72
R=–0.027, P=0.94
R=0.58, P=0.06
R=0.32, P=0.34
R=0.37, P=0.26
Figure 2
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
A
2000
1500
1000
500
0
0 100 200 300 400 500
Dose (mg)
C
m
a
x
 (n
g
/m
L
)
B
3000
2000
1000
0
0 100 200 300 400 500
Dose (mg)
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
o
n
 d
a
y
 5
 (
n
g
/m
L
)
Figure 3
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
K
i6
7
 p
e
rc
e
n
ta
g
e
 p
o
s
it
iv
e
 
c
e
lls
 (
%
)
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
K
i6
7
 p
e
rc
e
n
ta
g
e
 p
o
s
it
iv
e
 
c
e
lls
 (
%
)
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
K
i6
7
 p
e
rc
e
n
ta
g
e
 p
o
s
it
iv
e
 
c
e
lls
 (
%
)
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
p
P
R
A
S
4
0
 H
-s
c
o
re
 (
%
)
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
p
P
R
A
S
4
0
 H
-s
c
o
re
 (
%
)
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
p
G
S
K
3
b
 H
-s
c
o
re
 (
%
)
150
100
0
–50
–100
50
0 100 200 300 400 500
A
Dose (mg)
150
100
0
–50
–100
50
0 500 1000 1500 2000
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
p
G
S
K
3
b
 H
-s
c
o
re
 (
%
)
Day 1 Cmax
(ng/mL)
150
100
0
–50
–100
50
0 1000 2000 3000
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
p
G
S
K
3
b
 H
-s
c
o
re
 (
%
)
Day 5 concentration 
(ng/mL)
50
0
–50
–100
0 100 200 300 400 500
B
100
50
0
–50
–100
0 100 200 300 400 500
C
Dose (mg)
100
50
0
–50
–100
0 500 1000 1500 2000
Day 1 Cmax
(ng/mL)
100
50
0
–50
–100
0 1000 2000 3000
Day 5
concentration (ng/mL)
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
lin
e
 i
n
 
p
P
R
A
S
4
0
 H
-s
c
o
re
 (
%
)
Dose (mg)
50
0
–50
–100
0 500 1000 1500 2000
Day 1 Cmax
(ng/mL)
50
0
–50
–100
0 1000 2000 3000
Day 5 concentration 
(ng/mL)
Figure 4
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
 Published OnlineFirst December 13, 2019.Clin Cancer Res 
  
John FR Robertson, Robert E. Coleman, Kwok-Leung Cheung, et al. 
  
invasive breast cancer (STAKT)
Capivasertib (AZD5363) treatment of patients with ER+ 
Proliferation and AKT activity biomarker analyses after
  
Updated version
  
 10.1158/1078-0432.CCR-19-3053doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2019/12/13/1078-0432.CCR-19-3053.DC1
Access the most recent supplemental material at:
  
Manuscript
Author
been edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2019/12/13/1078-0432.CCR-19-3053
To request permission to re-use all or part of this article, use this link
Cancer Research. 
on December 17, 2019. © 2019 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 13, 2019; DOI: 10.1158/1078-0432.CCR-19-3053 
